Antiplatelet Therapy

February, 2022 Quick Question: Platelet Aggs

Our February 2022 Quick Question asks, What single agonist is your first choice to measure platelet response to aspirin? The typical aggregation profile includes several agonists, however it may be that one is more sensitive to aspirin’s antiplatelet effect than the others. As always, please add your comments below.

Antiplatelet Therapy

Primary CVD Disease: Is Low Dose ASA Effective?

Thanks to Dean Willett, Precision BioLogic Inc, for pointing me to this October 12, 2021 US Preventive Services Task Force release, “Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication,” which recommends against daily low-dose aspirin as a means to reduce the risk of cardiovascular disease, ischemic stroke, and colorectal cancer regardless of age or comorbities. […]

Antiplatelet Therapy

VWD and Aspirin

An acquaintance’s daughter has type 1 von Willebrand disease. Her OB physician recommends a daily baby aspirin during her pregancy. Are there any circumstances in which aspirin is indicated during pregnancy in a woman with VWD? Please provide your opinion in our Comments section below or email to [email protected] Thank you.

Antiplatelet Therapy

AUGUSTUS Trial: Apixaban and Clopidogrel

Click or tap here to learn the results of the AUGUSTUS trial, which shows that the combination of apixaban and a P2Y12 inhibitor such as clopidogrel is safer than Coumadin and clopidogrel, Coumadin and aspirin, or apixaban and aspirin for post-PCI or acute coronary syndrome therapy.

Anticoagulant Therapy

TWILIGHT Study: Discontinue Aspirin

Click or tap here to read and hear about the TWILIGHT trial outcomes that illustrate how three months after cardiac catheterization (PCI), aspirin may be discontinued. The trial showed that ticagrelor monotherapy was equally effective and safer than tacagrelor plus aspirin.

Antiplatelet Therapy

Aspirin Presentation October 16, 2019

Click here for George’s Northeast Laboratory Conference presentation handout, “Aspirin, the 1899 Wonder Drug Lives Again,” presented October 16, 2019 in Portland, Maine.

Antiplatelet Therapy

Zontivity (vorapaxar)

I’m curious about how many of our participants monitor vorapaxar (Zontivity®, New American Therapeutics, Inc) antiplatelet therapy. Vorapaxar is the only protease-activated receptor-1 (PAR-1) antagonist that reduces thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease, FDA-approved in 2014. Vorapaxar is used alongside dual antiplatelet therapy (aspirin and clopidogrel; aspirin and ticagrelor) […]

Antiplatelet Therapy

Aspirin Presentation June 26, 2019

Thanks to the American Society for Clinical Laboratory Science for providing George with the opportunity to present “Aspirin, the 1899 Wonder Drug Lives Again,” and thanks to the many participants who came to hear the talk. Click or tap here for an updated copy of the presentation handout. George will present an expanded version on […]

Antiplatelet Therapy

Ticagrelor Antibacterial Property

Click below to see a May 9, 2019 article that links ticagrelor (Brilinta) antiplatelet therapy with its putative anti-gram-positive bacterial property, including Methacillin-resistant Staph aureus and Vancomycin-resistant enterococcus. It appears that platelets are able to sequester the drug in sites of infection. Lancellotti P, Musumeci L, Jacques N, et al. Antibacterial activity of ticagrelor in […]

Antiplatelet Therapy

New Antiplatelet Therapy

I’ve attached a pre-pub article describing a phase I trial of ACT017, a novel antiplatelet antibody fragment specific for glycoprotein VI, a platelet membrane collagen receptor. The manufacturers propose that ACT017 infusion can suppress platelet activity as part of coronary artery disease therapy with minimal bleeding risk. Clip or tap the citation for full information: […]

Antiplatelet Therapy

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question